Treatment of ocular neovascularization using anti-VEGF proteins
US10004788B2 · kind B2 · utility
12Cited by
48References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 2017 |
| Grant date | Jun 26, 2018 |
| Priority date | — |
| Expiry date | Dec 21, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.